Full-Time

Senior Manager

Quality Control

Updated on 8/22/2026

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma focused on antibodies

Compensation Overview

$137.3k - $185k/yr

+ Annual Bonus Program + Long-Term Incentive Program

Sanford, NC, USA

In Person

This position is fully onsite in Sanford, North Carolina. It may require up to 10% domestic and limited international travel.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Microbiology

Get referred to Kyowa Kirin

See people who can refer or advise you

Requirements
  • A minimum bachelor's degree in a life science or related field.
  • At least five years of management experience leading good manufacturing practice biopharmaceutical Quality Control laboratories and associated support areas, including QC Sample Management, Microbiology, Raw Materials, Chemistry/Biochemistry, Stability, Bioassay, and/or Virology.
  • Proficiency in Empower, Laboratory Information Management Systems, Electronic Laboratory Notebooks, Laboratory Execution Systems, Microsoft Office Suite, Lean Lab practices, and Agile methodologies.
  • Ability to establish clear outcomes, track progress, follow through on commitments, adapt to change, organize work, maintain attention to detail, communicate empathetically, foster inclusive collaboration, drive innovation, and work across organizational silos.
  • Ability to comply with site personal protective equipment and dress-code requirements.
Responsibilities
  • Provide technical leadership and collaborate cross-functionally on facility design reviews, user requirements reviews, equipment and instrument prioritization, and implementation of electronic Quality Systems including Laboratory Information Management Systems, Electronic Laboratory Notebooks, and Empower.
  • Establish and maintain Quality Control procedures for the Site Quality Management System Laboratory Controls Sub-system and develop training requirements for QC staff.
  • Lead and coordinate implementation of analytical and microbiological test methods through development, qualification or optimization, validation or compendial-method suitability, and transfer.
  • Establish a raw materials sampling, testing, and release program in compliance with applicable regulatory requirements, including Japanese Pharmacopoeia, United States Pharmacopeia, and European Pharmacopoeia.
  • Coordinate testing and reporting of laboratory results for Environmental Monitoring and Utility Monitoring programs.
  • Lead QC laboratory operations through validation and qualification activities for the facility, equipment, analytical instruments, and computerized systems required for commissioning and operational readiness.
  • Ensure laboratory electronic systems and records comply with current 21 CFR Part 11 and ALCOA++ data-integrity requirements.
  • Hire, onboard, train, and mentor QC staff according to approved staffing plans.
  • Lead investigations of deviations, laboratory exceptions, and other current good manufacturing practice issues, and initiate and communicate corrective and preventive actions.
  • Establish key performance indicators for the QC laboratories, including out-of-specification results, invalid assays, out-of-trend results, laboratory deviations, testing turnaround times, and environmental-monitoring data trends.
  • Implement and manage the site's Contamination Control Strategy cross-functionally.
  • Assist the Quality Site Head in identifying and qualifying contracted laboratory services or contingent staffing.
  • Lead QC laboratory activities in response to regulatory requests and support regulatory and internal inspections of the facility and laboratory areas.
  • Set measurable goals, align resources, remove obstacles, and maintain accountability for team objectives.
  • Provide constructive feedback, handle conflicts thoughtfully, create growth plans, support learning, and develop the team.
  • Build an inclusive and respectful environment, promote collaboration, manage stakeholders, build alignment, and guide teams through change and uncertainty.
Desired Qualifications
  • A master's degree in a life science or related field.
  • Experience supporting the start-up and operation of a biopharmaceutical manufacturing facility.

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Crysvita gained EU infant approval in July 2026, extending exclusivity through February 2030.
  • Sanford construction is on track for 2027, supporting U.S. supply and margins.
  • Link Cell Therapies and Cimeio deals deepen cell-therapy optionality for 2027-2028.

What critics are saying

  • Rocatinlimab trials stopped March 2026 after safety concerns, destroying a blockbuster thesis.
  • Crysvita still anchors results, leaving Kyowa Kirin exposed to concentration risk.
  • Amgen exited rocatinlimab in January 2026; partnership churn threatens late-stage execution.

What makes Kyowa Kirin unique

  • Crysvita dominated 2025 revenue at ¥216.4 billion, proving rare-disease depth.
  • Kyowa Kirin won FDA PreCheck for Sanford, accelerating U.S. biologics manufacturing.
  • Ziftomenib launched in November 2025, giving Kyowa Kirin an oncology commercial platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.